Evidence map›Paper›PMID 41226001›Full record

ReviewDiagnostics (Basel, Switzerland)2025

The Value of Circulating Tumor HPV DNA in Head and Neck Squamous Cell Cancer: A Review.

Rüveyda Dok, Sandra Nuyts, Fernando Lopez, Carol Bradford, Arlene A Forastiere, Primož Strojan, Abbas Agaimy, Göran Stenman, Fernanda V Mariano, Ilmo Leivo and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rüveyda DokLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, University of Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-5456-814X
Sandra NuytsLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, University of Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-5540-4796
Fernando LopezENT and Head and Neck Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Carol BradfordDepartment of Otolaryngology-Head and Neck Surgery, The Ohio State University College of Medicine, Columbus, OH 43210, USA.
Arlene A ForastiereThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA.ORCID 0000-0003-2238-3682
Primož StrojanDepartment of Radiotherapy, Institute of Oncology Ljubljana, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-0445-112X
Abbas AgaimyComprehensive Cancer Center (CCC) Erlangen-EMN, Institute of Pathology, University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Göran StenmanDepartment of Laboratory Medicine/Pathology, Sahlgrenska Center for Cancer Research, Sahlgrenska University Hospital, University of Gothenburg, 405 30 Gothenburg, Sweden.ORCID 0000-0003-1017-7363
Fernanda V MarianoDepartment of Pathology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas 13083-970, SP, Brazil.
Ilmo LeivoInstitute of Biomedicine, Pathology, University of Turku, Turku University Hospital, 20520 Turku, Finland.
Karthik N RaoDepartment of Head and Neck Oncology, Sri Shankara Cancer Hospital and Research Centre, Bangalore 560 004, India.ORCID 0000-0002-1420-7366
Michelle WilliamsDepartment of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9133-7332
Avraham EisbruchDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Nabil F SabaDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0003-4972-1477
Alfio FerlitoThe International Head and Neck Scientific Group, 35100 Padua, Italy.ORCID 0000-0002-8247-8002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCC) represent a distinct subgroup of head and neck squamous cell carcinoma (HNSCC) characterized by better prognosis and increased radiosensitivity compared to HPV-negative OPSCC. However, current diagnostic and monitoring methods, including tissue biopsies and imaging, are insufficient for precise risk stratification and early detection of recurrence, leading to challenges in treatment de-escalation and surveillance strategies. Circulating tumor HPV DNA (ctHPV-DNA) has emerged as a promising minimally invasive biomarker that offers tumor-specific detection and monitoring capabilities, potentially transforming the management of HPV-related OPSCC through early disease detection, treatment response assessment, recurrence surveillance stratification, and disease monitoring. Despite encouraging results from early clinical studies, current use is limited to trial settings. Large-scale prospective studies are needed to validate its clinical utility and determine whether early ctHPV-DNA testing can improve patient outcome while reducing treatment related morbidity. This review outlines the biological rationale, technological approaches, and current clinical evidence for ctHPV-DNA in HPV-related OPSCC, emphasizing its potential role in treatment monitoring and surveillance.

Indexed as

ctDNActHPV-DNAhead and neck squamous cell carcinomahuman papillomavirus

Identifiers

PMID41226001
PMCPMC12609682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.